Paragraph: Angioedema treatment refers to medication prescribed to treat angioedema, which is an allergic condition causing swelling under the skin. The swelling occurs in the deep layers of the skin and tissues just below it. Some of the commonly prescribed angioedema treatment drugs are C1-esterase inhibitors, bradykinin receptor antagonists, and selective Bradykinin B2 receptor antagonists. These drugs help reduce inflammation, prevent future attacks, and provide quick relief from symptoms. The global Angioedema Treatment Market is estimated to be valued at US$ 470.4 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: Hereditary angioedema (HAE) is a rare genetic condition that causes severe swelling in various body parts. The incidence of HAE is estimated to be around 1 in 50,000 people globally. With no definite cure available, lifelong treatment is required to manage the symptoms of repeated swelling attacks. The increasing prevalence of HAE drives the demand for drugs that can effectively treat swelling episodes and prevent future attacks. Developed regions with advanced healthcare facilities have reported high diagnosis rates of HAE, leading to growing treatment uptake. Novel drug delivery formulations and pipeline molecules that offer more targeted treatment options are also fueling market growth.
SWOT Analysis
Strength: The increasing prevalence of hereditary angioedema, growing R&D investments, and rising awareness are driving the growth of the market.
Weakness: High treatment costs and lack of awareness in low-income countries hampers the market growth.
Opportunity: Growing healthcare infrastructure in emerging economies presents numerous growth opportunities in the forecast period.
Threats: Stringent regulatory framework and patent expiration of blockbuster drugs are major challenges for players in the market.
Key Takeaways
The global Angioedema Treatment market is expected to witness high growth. North America dominates the market currently due to increasing prevalence of HAE, advanced healthcare infrastructure, and high healthcare expenditure. According to estimates, the North America Angioedema Treatment market is projected to reach ~US$ 230 Mn by 2030.
Key players operating in the Angioedema Treatment market are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd. These key players are focusing on new product launches, collaborations, and geographical expansions to increase their market share. For instance, in 2022, Zoetis Inc. launched a new drug called Skypaxxa indicated for the treatment of hereditary angioedema in dogs.
The Asia Pacific region offers lucrative growth opportunities with rising healthcare expenditure, increasing patient pool, and growing adoption of advanced treatments. Countries like China, India, Japan, and South Korea are expected to be major revenue pockets in the coming years.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
